Active, not recruitingPhase 2NCT05119569

A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)

Studying Opsoclonus-myoclonus syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Hoffmann-La Roche
Principal Investigator
Clinical Trials
Hoffmann-La Roche
Intervention
Fenebrutinib(drug)
Enrollment
109 target
Eligibility
18-55 years · All sexes
Timeline
20222026

Study locations (17)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05119569 on ClinicalTrials.gov

Other trials for Opsoclonus-myoclonus syndrome

Additional recruiting or active studies for the same condition.

See all trials for Opsoclonus-myoclonus syndrome

← Back to all trials